Galectin Therapeutics (GALT) Other Non-Current Liabilities (2010 - 2026)
Galectin Therapeutics (GALT) recorded quarterly Other Non-Current Liabilities of $3.0 million in Q1 2026, down 24.81% quarter-over-quarter from $4.0 million in Q4 2025, and up 2090.44% on a YoY basis from $136000.0 in Q1 2025.
Galectin Therapeutics (GALT) Other Non-Current Liabilities (2010 - 2026) Analysis & Trends
Galectin Therapeutics' Other Non-Current Liabilities history runs 12 years deep, the most recent figure standing at $3.0 million for Q1 2026.
- In Q1 2026, Other Non-Current Liabilities rose 2090.44% year-over-year to $3.0 million; the TTM figure through Mar 2026 stood at $3.0 million (up 2090.44% YoY), while the FY2025 annual figure was $4.0 million, up 8329.79% from the prior year.
- Other Non-Current Liabilities was $3.0 million for Q1 2026 at Galectin Therapeutics, down from $4.0 million in the prior quarter.
- In the past five years, Other Non-Current Liabilities ranged from a high of $4.0 million in Q4 2025 to a low of $47000.0 in Q4 2024.
- Historically, Other Non-Current Liabilities has averaged $773312.5 across 5 years, with a median of $291500.0 in 2022.
- The sharpest annual moves came in 2024 and 2025: Other Non-Current Liabilities slumped 88.37% in 2024, then soared 8329.79% in 2025.
- A 5-year view of Other Non-Current Liabilities shows it stood at $214000.0 in 2022, then soared by 88.79% to $404000.0 in 2023, then plunged by 88.37% to $47000.0 in 2024, then jumped by 8329.79% to $4.0 million in 2025, then decreased by 24.81% to $3.0 million in 2026.
- The last three Other Non-Current Liabilities figures came in at $3.0 million (Q1 2026), $4.0 million (Q4 2025), and $1.5 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Galectin Therapeutics | 185.83 Mn | 171.73 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.98 Mn |
| Dec 31, 2025 | 3.96 Mn |
| Jun 30, 2025 | 1.54 Mn |
| Mar 31, 2025 | 136,000.00 |
| Dec 31, 2024 | 47,000.00 |
| Sep 30, 2024 | 957,000.00 |
| Jun 30, 2024 | 309,000.00 |
| Mar 31, 2024 | 307,000.00 |
| Dec 31, 2023 | 404,000.00 |
| Sep 30, 2023 | 238,000.00 |
| Jun 30, 2023 | 366,000.00 |
| Mar 31, 2023 | 276,000.00 |
| Dec 31, 2022 | 214,000.00 |
| Sep 30, 2022 | 177,000.00 |
| Jun 30, 2022 | 276,000.00 |
| Mar 31, 2022 | 188,000.00 |
| Dec 31, 2021 | 384,000.00 |
| Sep 30, 2021 | 1.19 Mn |
| Sep 30, 2020 | 19,000.00 |
| Jun 30, 2020 | 31,000.00 |